Biomx Ltd (PHGE) Stock Price, Quote & News

Company Profile

BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from...

Industry: Biotechnology

Sector: Healthcare

Website: www.biomx.com

Address:

850 New Burton Road, Suite 201, Dover, United States

toffernelson Mar. 16 at 4:42 PM

$PHGE Low volume melt down. $0.20 spread on bid/ask. There’s nothing to indicate thesis is off track. High risk high reward. If nothing happens, it’s a $2 stock. If thesis executes, I think it’s $20+.

0 · Reply

OfficialStocktwitsUser Mar. 16 at 4:41 PM

$PHGE RSI: 56.56, MACD: 0.4043 Vol: 1.00, MA20: 5.56, MA50: 4.71 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Louisisngleton Mar. 16 at 1:17 PM

$PHGE was expecting something in pre market…. Guess not 🤷‍♂️

1 · Reply

simplifocused Mar. 16 at 12:53 AM

$TPET Never to miss opportunities, $PHGE might surprise? NFA

0 · Reply

ASseenONtv Mar. 15 at 10:22 PM

$PHGE Can we stop with the $150 share price prediction? We have to get to $10 first.

1 · Reply

Blind_Trader_ Mar. 14 at 8:01 AM

$PHGE @toffernelson show your position. dont believe a single word out of his mouth

2 · Reply

Louisisngleton Mar. 13 at 4:08 PM

$PHGE would love to see more chatter on here. Looking at recent filings and appointments I think it’s a given this ticker is merging to form a new entity. Would be interested to see what people are expecting! Assuming we will hear something after hours today.

1 · Reply

cupcakes4jesus Mar. 12 at 8:40 PM

$PHGE I can feel it coming deep in my loins

2 · Reply

cupcakes4jesus Mar. 12 at 2:24 PM

$PHGE gonna be $50 tomorrow or Monday

2 · Reply

IggyRila Mar. 12 at 2:03 PM

$PHGE added more today

0 · Reply

BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

Jan 27, 2026, 1:41 PM EST - 6 weeks ago

BiomX Issues Statement Regarding Recent Common Stock Trading Activity

Dec 29, 2025, 8:00 AM EST - 2 months ago

BiomX Announces $3.0 Million Private Placement

Nov 26, 2025, 1:23 PM EST - 3 months ago

BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review

Nov 25, 2025, 4:40 PM EST - 3 months ago

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

Nov 12, 2025, 10:31 AM EST - 4 months ago

BiomX Inc. (PHGE) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:30 AM EST - 4 months ago

BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

Oct 17, 2025, 8:30 AM EDT - 5 months ago

BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

Aug 19, 2025, 8:19 AM EDT - 7 months ago

BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis

Aug 13, 2025, 11:48 AM EDT - 7 months ago

BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 6:30 AM EDT - 7 months ago

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

Aug 6, 2025, 8:30 AM EDT - 7 months ago

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

Jul 14, 2025, 9:00 AM EDT - 8 months ago

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

Jul 8, 2025, 8:30 AM EDT - 8 months ago

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

May 19, 2025, 10:02 AM EDT - 10 months ago

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 15, 2025, 4:57 PM EDT - 10 months ago

BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 6:30 AM EDT - 10 months ago

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 8, 2025, 7:00 AM EDT - 11 months ago

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

Apr 1, 2025, 6:30 AM EDT - 1 year ago

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

Mar 31, 2025, 6:30 AM EDT - 1 year ago

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

Mar 25, 2025, 6:30 AM EDT - 1 year ago

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

Mar 19, 2025, 12:35 PM EDT - 1 year ago

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Nov 14, 2024, 10:20 AM EST - 1 year ago

BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 6:30 AM EST - 1 year ago

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

Nov 12, 2024, 12:20 PM EST - 1 year ago

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

Oct 15, 2024, 7:00 AM EDT - 1 year ago

BiomX Announces a Mandatory Unit Separation

Sep 18, 2024, 8:00 AM EDT - 1 year ago

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

Sep 4, 2024, 8:00 AM EDT - 1 year ago

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 10:55 AM EDT - 1 year ago

UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

Aug 15, 2024, 12:03 PM EDT - 1 year ago

BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 6:30 AM EDT - 1 year ago

BiomX Inc. Announces 1-for-10 Reverse Stock Split

Aug 15, 2024, 6:30 AM EDT - 1 year ago

BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024

Jul 31, 2024, 7:35 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Explode In Q3

DXCM EW

Jul 29, 2024, 7:00 AM EDT - 1 year ago

BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Jul 10, 2024, 6:30 AM EDT - 1 year ago

BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock

May 30, 2024, 4:50 PM EDT - 1 year ago

BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

May 30, 2024, 7:00 AM EDT - 1 year ago

BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024

May 21, 2024, 10:25 AM EDT - 1 year ago

BiomX (PHGE) Q1 2024 Earnings Call Transcript

May 21, 2024, 6:30 AM EDT - 1 year ago

BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates

May 15, 2024, 7:00 AM EDT - 1 year ago

BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024

Apr 23, 2024, 8:00 AM EDT - 2 years ago

BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)

Apr 18, 2024, 8:00 AM EDT - 2 years ago

BiomX Announces the Appointment of Susan Blum to its Board of Directors

Apr 3, 2024, 12:26 PM EDT - 2 years ago

BiomX Inc. (PHGE) Q4 2023 Earnings Call Transcript

Apr 3, 2024, 6:30 AM EDT - 2 years ago

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 27, 2024, 6:30 AM EDT - 2 years ago

BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024

Mar 18, 2024, 6:30 AM EDT - 2 years ago

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Mar 6, 2024, 7:30 AM EST - 2 years ago

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Jan 4, 2024, 8:00 AM EST - 2 years ago

BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis

toffernelson Mar. 16 at 4:42 PM

0 · Reply

OfficialStocktwitsUser Mar. 16 at 4:41 PM

0 · Reply

Louisisngleton Mar. 16 at 1:17 PM

$PHGE was expecting something in pre market…. Guess not 🤷‍♂️

1 · Reply

simplifocused Mar. 16 at 12:53 AM

$TPET Never to miss opportunities, $PHGE might surprise? NFA

0 · Reply

ASseenONtv Mar. 15 at 10:22 PM

$PHGE Can we stop with the $150 share price prediction? We have to get to $10 first.

1 · Reply

Blind_Trader_ Mar. 14 at 8:01 AM

$PHGE @toffernelson show your position. dont believe a single word out of his mouth

2 · Reply

Louisisngleton Mar. 13 at 4:08 PM

1 · Reply

cupcakes4jesus Mar. 12 at 8:40 PM

$PHGE I can feel it coming deep in my loins

2 · Reply

cupcakes4jesus Mar. 12 at 2:24 PM

$PHGE gonna be $50 tomorrow or Monday

2 · Reply

IggyRila Mar. 12 at 2:03 PM

$PHGE added more today

0 · Reply

Louisisngleton Mar. 12 at 1:26 PM

$PHGE https://g.co/gemini/share/f154706cddaa

0 · Reply

Bigtimebigshot77 Mar. 12 at 12:31 AM

$PHGE hey but Neil said iT was good. Lmao

1 · Reply

SuperGreenToday Mar. 11 at 7:52 PM

$PHGE

0 · Reply

toffernelson Mar. 11 at 6:43 PM

$PHGE Added another 1,000. There’s nothing to indicate it’s off track from thesis. Low volume takes it up fast and low volume takes it down fast.

1 · Reply

elidan Mar. 11 at 5:34 PM

$PHGE good work friend

0 · Reply

cupcakes4jesus Mar. 11 at 3:52 PM

$PHGE @toffernelson any thoughts on what you expect? Down 13% today… thought they had an “important meeting” this morning. What’s your thoughts?

1 · Reply

elidan Mar. 11 at 8:01 AM

$PHGE maybe today are the big news?

0 · Reply

toffernelson Mar. 10 at 7:09 PM

$PHGE Added 5,000. We’re on track with my thesis. The New CEO, Michael Oster, is not a biotech executive. His profile is pure M&A and Defense/Aerospace. He is a board member of BladeRanger Ltd., which the release explicitly describes as an innovator in "advanced drone payload systems for defense, homeland security, and solar applications." He was the Senior VP of M&A at Alon USA Energy, handling an $8 billion revenue operation. This is the profile of someone hired to "buy and build" a conglomerate, not to run clinical trials for bacteria. The New CFO, David Rokach, he has been a member of the board of directors of T3 Defense Inc. since 2024. He has 20 years of experience managing hedge funds and strategic financial initiatives in Israel.

0 · Reply

elidan Mar. 10 at 5:03 PM

$PHGE 150$

1 · Reply

cupcakes4jesus Mar. 10 at 3:34 PM

$PHGE added some. Can someone tell me where the stock would go on a drone deal announcement?

2 · Reply

Bigtimebigshot77 Mar. 10 at 1:19 AM

$PHGE hey if Neil is posting about this you’re all but guaranteed to lose money.

0 · Reply

DUETIME123 Mar. 9 at 5:57 PM

$PHGE I expect news about the merger at the latest this Thursday, so anytime between today and Thursday.

2 · Reply

Market Cap	9.87M
Revenue (ttm)	0.00
Net Income (ttm)	-36.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	63,717
Avg Vol	1,226,244
Day's Range	N/A - N/A
Shares Out	1.59M
Stochastic %K	53%
Beta	1.68
Analysts	Hold
Price Target	$26.00